The DOI matches its Crossref record.
Receptor Targeting for Tumor Localisation and Therapy with Radiopeptides
Abstract
Receptor targeting with radiolabeled peptides has become very important in nuclear oncology in the past few years. The most frequently used peptides in the clinic are analogs of somatostatin (SRIF), e.g. OctreoScan, which contain chelators for the radioisotopes 111 In, 86Y, 90 Y, 67Ga, 68Ga and 64Cu or for 99m Tc and 188Re. and were labelled with the halogens 123I and 18F. Radiolabeled analogs of a-melanocyte-stimulating hormone (a-MSH), neurotensin, vasoactive intestinal peptide (VIP), bombesin (BN), substance P (SP) and gastrin/cholecystokinin (CCK) are also being developed, evaluated in vitro and in vivo and tested for clinical application. This review focuses on the expression in tumors and the regulation of receptors for these neuropeptides as well as the development of novel chelator-peptide conjugates suitable for in vivo scintigraphy or internal radiotherapy. The state of the art of radiopeptide pharmaceuticals is illustrated with four SRIF analogs, modified with the macrocyclic chelator 1, 4, 7, 10-tetraazacyclododecane- 1, 4, 7, 10-tetraacetic acid (DOTA) (D-Phe 1 )-octreotide (DOTAOC), [D-Phe 1 , Tyr 3 )-octreotide (DOTATOC), vapreotide (DOTAVAP) and lanreotide (DOTALAN). DOTA is almost a universal chelator capable of strongly encapsulating hard metals such as 111 In and 67 Ga for Single Photon Emission Tomography (SPET), 68 Ga, 86 Y and 64 Cu for Positron Emission Tomography (PET) as well as 90 Y for receptor-mediated radionuclide therapy and radiolanthanides which exhibit different interesting decay schemes. From biodistribution studies in experimental animals and from clinical data it is concluded that DOTATOC is currently the most suitable SRIF radiopeptide with the best potential in the clinic. Keywords: radiopeptides, melanocyte stimulating hormone MSH, neurotensin, vasoactive, tetraazacyclododecane 1 4 7 10 tetraacetic acid DOTA, D phe 1 octerotide DOTAOC D Phe1 Tyr3, vapreotide DITAVAP, lanreodtide DOTALAN, positron emission tomography PET, radioiodiantion fluorination, diethylenetriaminepentacetic acid DTPA, bifunctional chelating BFCs, melanocyte stimulating hormonev, vasoactive intestinal peptide, subtance P, cholecystokinin B gastrin, bombesin
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
Reubi, J. C. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0007 · Cited by 1,131
Gabriel, M., Decristoforo, C., Kendler, D., Dobrozemsky, G., Heute, D., Uprimny, C., Kovacs, P., Von Guggenberg, E., Bale, R., & Virgolini, I. J. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.035667 · Cited by 1,010
Tumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule
Orlova, A., Magnusson, M., Eriksson, T. L. J., Nilsson, M., Larsson, B., Höidén-Guthenberg, I., Widström, C., Carlsson, J., Tolmachev, V., Ståhl, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3521 · Cited by 568
Hofmann, M., Maecke, H., Börner, A., Weckesser, E., Schöffski, P., Oei, M., Schumacher, J., Henze, M., Heppeler, A., Meyer, G., et al. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100639 · Cited by 544
Self-citationGinj, M., Zhang, H., Waser, B., Cescato, R., Wild, D., Wang, X., Erchegyi, J., Rivier, J., Mäcke, H. R., & Reubi, J. C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607761103 · Cited by 515
Liu, S. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.006 · Cited by 420
Liu, S. (2009) · Bioconjugate Chemistry · doi:10.1021/bc900167c · Cited by 344
Wild, D., Schmitt, J. S., Ginj, M., Mäcke, H. R., Bernard, B. F., Krenning, E., de Jong, M., Wenger, S., & Reubi, J.-C. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1255-5 · Cited by 310
Radiolabelling DOTA-peptides with 68Ga
Breeman, W. A. P., de Jong, M., de Blois, E., Bernard, B. F., Konijnenberg, M., & Krenning, E. P. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1702-y · Cited by 291
Phage display screening of therapeutic peptide for cancer targeting and therapy
Saw, P. E., & Song, E.-W. (2019) · Protein & Cell · doi:10.1007/s13238-019-0639-7 · Cited by 279
The Synthesis and Chelation Chemistry of DOTA−Peptide Conjugates
De León-Rodríguez, L. M., & Kovacs, Z. (2008) · Bioconjugate Chemistry · doi:10.1021/bc700328s · Cited by 262
Peptide Receptor Radionuclide Therapy: An Overview
Dash, A., Chakraborty, S., Pillai, M. R. A., & Knapp, F. F. (. (2015) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2014.1741 · Cited by 128
Nuclear medicine in the detection and management of pancreatic islet-cell tumours.
Virgolini, I., Traub-Weidinger, T., & Decristoforo, C. (2005) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.09.001 · Cited by 93
Metadata
- Authors
- Heppeler, A., Froidevaux, S., Eberle, A., & Maecke, H.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2000-09-01
- Volume
- 7
- Issue
- 9
- Pages
- 971-994
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2169983485
- Cited by
- 258
- References
- 0
- FWCI
- 11.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.